FibroBiologics, Inc. Common Stock (FBLG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FibroBiologics, Inc. Common Stock (FBLG) has a cash flow conversion efficiency ratio of -31.776x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.97 Million) by net assets ($125.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see FibroBiologics, Inc. Common Stock (FBLG) total market value for the company's overall valuation and market capitalisation.
FibroBiologics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how FibroBiologics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
FibroBiologics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FibroBiologics, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore how high is FibroBiologics, Inc. Common Stock's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Planet Green Holdings Corp
NYSE MKT:PLAG
|
0.211x |
|
Alankit Limited
NSE:ALANKIT
|
0.080x |
|
Bumi Benowo Sukses Sejahtera Pt
JK:BBSS
|
-0.003x |
|
The Beachbody Company, Inc.
NASDAQ:BODI
|
-0.147x |
|
IMS SA
WAR:IMS
|
0.157x |
|
Nord Insuretech Group AB
ST:NORDIG
|
0.533x |
|
Ulima Nitra PT
JK:UNIQ
|
0.040x |
|
Alpcot Holding AB Series B
ST:ALPCOT-B
|
-0.159x |
Annual Cash Flow Conversion Efficiency for FibroBiologics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of FibroBiologics, Inc. Common Stock from 2022 to 2025. View current stock price of FibroBiologics, Inc. Common Stock for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $2.73 Million | $-11.90 Million | -4.351x | +14.82% |
| 2024-06-30 | $1.25 Million | $-6.40 Million | -5.109x | -602.06% |
| 2023-06-30 | $-4.00 Million | $-4.07 Million | 1.018x | -6.91% |
| 2022-06-30 | $-1.29 Million | $-1.41 Million | 1.093x | -- |
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.